Destiny Pharma PLC Appointment of Nominated Adviser and Sole Broker (3547A)
22 Enero 2024 - 1:00AM
UK Regulatory
TIDMDEST
RNS Number : 3547A
Destiny Pharma PLC
22 January 2024
Destiny Pharma plc
("Destiny Pharma" or "the Company")
Appointment of Nominated Adviser and Sole Broker
Brighton, United Kingdom - 22 January 2024 - Destiny Pharma
(AIM: DEST), a clinical stage biotechnology company focused on the
development and commercialisation of novel medicines to prevent and
cure life threatening infections, is pleased to announce the
appointment of Shore Capital and Corporate Limited as its Nominated
Adviser and Shore Capital Stockbrokers Limited as its Sole Broker
with immediate effect.
- END -
For further information, please contact:
Destiny Pharma plc
Chris Tovey, CEO
Shaun Claydon, CFO
+44 (0) 127 370 4440
pressoffice@destinypharma.com
Shore Capital (Nominated Adviser and Broker)
Daniel Bush / James Thomas / Lucy Bowden
+44 (0) 207 408 4090
FTI Consulting (Financial PR)
Ben Atwell / Simon Conway / Michael Trace / Victoria Foster
Mitchell
+44 (0) 203 727 1000
destinypharma@fticonsulting.com
About Destiny Pharma
Destiny Pharma is an innovative, clinical-stage biotechnology
company focused on the development and commercialisation of novel
medicines that can prevent life-threatening infections. The
company's drug development pipeline includes two late stage assets
NTCD-M3, a microbiome-based biotherapeutic for the prevention of C.
difficile infection (CDI) recurrence which is the leading cause of
hospital acquired infection in the US, and XF-73 nasal gel, a
proprietary drug targeting the prevention of post-surgical
staphylococcal hospital infections including MRSA.
For further information on the company, please visit
www.destinypharma.com
Existing Board - AIM Rule 17 Disclosures
The Group announces the following information is being disclosed
pursuant to Rule 17 and Schedule Two Paragraph (g) of the AIM Rules
for Companies:
Sir Nigel Rudd - Chairman
Sir Nigel Rudd is a director of Loch Lomond Members Golf Club
Limited. He was appointed on 29 November 2010; as such this was a
current directorship at the date of the Company's announcement
entitled "Appointment of new Chairman" dated 25 July 2023.
Christopher Tovey - Chief Executive Officer
Christopher Tovey was a former director of GW Pharma (Germany)
GmbH and GW Pharma (France) SARL within 5 years of the date of the
Company's announcement entitled "Board changes including
appointment of new CEO" dated 19 July 2023.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
APPBLGDBCUBDGSC
(END) Dow Jones Newswires
January 22, 2024 02:00 ET (07:00 GMT)
Destiny Pharma (LSE:DEST)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Destiny Pharma (LSE:DEST)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
